Brain Motion Aurora-B (06681): Participated in major national science and technology research projects and was approved by the Beijing Key Laboratory for Digital Medicine for Cognitive Disorders

Zhitong Finance App News, Brain Motion Aurora-B (06681) issued an announcement. Beijing Zhi Jing Ling Technology Co., Ltd. (Smart Genie Technology), a wholly-owned subsidiary of the company, is participating as an important partner in the major national science and technology project “Cancer, Cardiovascular, Respiratory and Metabolic Disease Prevention Research” project. The title of the topic is “Establishment and Scenario-based Application of Key Techniques for Digital Diagnosis and Treatment of Cognitive Disorders Related to Intracranial Atherosclerosis and Stenosis Based on Deep Reasoning” (Project Number: 2025ZD0546200) (National Science and Technology Project). This project has been officially launched recently. At the same time, the “Beijing Key Laboratory for Digital Medicine for Dementia”, which was jointly declared by Smart Genesis Technology and Xuanwu Hospital (Xuanwu Hospital) of Capital Medical University (Xuanwu Hospital), has also recently been officially approved for establishment.

The major national science and technology projects undertaken by the company and the approval of the Beijing Key Laboratory have fully demonstrated the company's leading position in technology in the field of digital diagnosis and treatment of cognitive impairment.

The incidence of intracranial atherosclerotic stenosis (“ICAS”) among people aged 35 and over in China is as high as 13%. Irreversible damage to brain tissue caused by ICAS causes cognitive impairment mainly characterized by memory loss, language impairment, and executive impairment. Although nearly half of patients with moderate to severe ICAS have cognitive impairment, there is currently a lack of effective early diagnosis and treatment methods.

The major national science and technology project launched this time focuses on the diagnosis and treatment problems of ICAS-related cognitive impairment, and carries out systematic research based on interdisciplinary advantages. The core direction includes establishing an evaluation technology system for ICAS-related cognitive impairment and a large-scale model for deep inference prediction to provide diagnosis and treatment tools for early disease screening, risk prediction, prevention, and intervention, and establishing a closed-loop management system for ICAS-related cognitive impairment.

The implementation of this project aims to establish an internationally leading ICAS-related cognitive impairment diagnosis and treatment technology system, establish a disease management model that conforms to China's national conditions, effectively prevent and delay disease progression, and help the “Healthy China” strategy. The project was led by Xuanwu Hospital and collaborated with Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, the Institute of Psychology of the Chinese Academy of Sciences, Jilin University, Beijing Normal University, and Smart Genie Technology. The research team brought together top experts in the fields of neurology, cognitive neuroscience, psychology and artificial intelligence, and maintained long-term cooperation with leading international research teams. They have published many important results in top journals such as Science and Cell, providing a solid guarantee for the successful implementation of the project.

Major national science and technology projects are major science and technology plans to achieve the country's strategic goals and break through core key technologies. This project is a major national science and technology project in the field of digital diagnosis and treatment of neurocognitive impairment in China, indicating that this direction has been raised to the level of national strategic scientific research. As a pioneer in the deep integration of brain science and artificial intelligence technology, the company relies on technology and data accumulation in the field of digital diagnosis and treatment of neurological and psychiatric diseases, and will undertake technical research and development of ICAS-related deep inference models and the construction of a digital diagnosis and treatment platform in the project.

Furthermore, the Beijing Key Laboratory for Digital Therapy for Dementia was built by the deep integration of the four forces of clinical medicine, basic research, technology development, and hardware innovation to form a collaborative model of “clinically driven, basic support, software and hardware integration, and penetrating transformation”. As the core technology undertaker, the company is mainly responsible for core algorithm development, commercialization and user experience optimization of the digital medical platform for cognitive impairment. The laboratory will rely on the advantages of multiple resources, including artificial intelligence focused on by the company, to enable core technology research and development, clinical transformation and industry standard setting for digital diagnosis and treatment of cognitive impairment, build a high-level academic exchange and talent training platform, promote the deep integration of digital medical technology with clinical diagnosis and treatment, and provide continuous impetus for industry innovation and development.